Brokerages Set InVitae Corp (NASDAQ:NVTA) Target Price at $15.00

InVitae Corp (NASDAQ:NVTA) has been assigned a consensus rating of “Hold” from the seven analysts that are covering the company, Marketbeat reports. Three equities research analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and three have given a buy recommendation to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $15.00.

Several brokerages recently weighed in on NVTA. BidaskClub upgraded InVitae Corp from a “sell” rating to a “hold” rating in a research note on Thursday, August 3rd. Zacks Investment Research downgraded InVitae Corp from a “hold” rating to a “sell” rating in a research note on Tuesday, July 18th. Finally, ValuEngine upgraded InVitae Corp from a “strong sell” rating to a “sell” rating in a research note on Friday, June 2nd.

InVitae Corp (NASDAQ:NVTA) opened at 9.23 on Friday. The company’s market capitalization is $390.56 million. The stock’s 50 day moving average price is $9.56 and its 200-day moving average price is $9.76. InVitae Corp has a one year low of $5.76 and a one year high of $11.88.

InVitae Corp (NASDAQ:NVTA) last announced its earnings results on Monday, August 7th. The medical research company reported ($0.66) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.64) by $0.02. InVitae Corp had a negative return on equity of 119.10% and a negative net margin of 260.48%. The business had revenue of $14.34 million for the quarter, compared to analysts’ expectations of $13.31 million. During the same quarter last year, the firm earned ($0.77) earnings per share. The firm’s quarterly revenue was up 157.0% compared to the same quarter last year. Equities analysts forecast that InVitae Corp will post ($2.42) EPS for the current year.

A number of hedge funds have recently modified their holdings of NVTA. Donald L. Hagan LLC purchased a new stake in shares of InVitae Corp during the first quarter worth approximately $111,000. Verity Asset Management Inc. purchased a new stake in shares of InVitae Corp during the first quarter worth approximately $116,000. Nationwide Fund Advisors boosted its stake in shares of InVitae Corp by 21.1% in the first quarter. Nationwide Fund Advisors now owns 17,121 shares of the medical research company’s stock worth $189,000 after buying an additional 2,987 shares in the last quarter. American International Group Inc. boosted its stake in shares of InVitae Corp by 31.3% in the first quarter. American International Group Inc. now owns 17,174 shares of the medical research company’s stock worth $190,000 after buying an additional 4,090 shares in the last quarter. Finally, Trexquant Investment LP purchased a new stake in shares of InVitae Corp during the first quarter worth approximately $200,000.

WARNING: “Brokerages Set InVitae Corp (NASDAQ:NVTA) Target Price at $15.00” was posted by BBNS and is the sole property of of BBNS. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this news story can be viewed at https://baseballnewssource.com/markets/invitae-corp-nasdaqnvta-receives-average-rating-of-hold-from-analysts-updated-updated-updated/1197917.html.

InVitae Corp Company Profile

Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients.

Receive News & Ratings for InVitae Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVitae Corp and related companies with our FREE daily email newsletter.

 


Latest News

Kris Bryant Back in Spotlight, Cubs Pushing for Playoff Berth
Kris Bryant Back in Spotlight, Cubs Pushing for Playoff Berth
Despite Changes to Reduce The Length of Games, MLB Games are Actually Getting Longer
Despite Changes to Reduce The Length of Games, MLB Games are Actually Getting Longer
Despite Hitting Home Run, Judge Sets Longest Game Streak for Strikeouts
Despite Hitting Home Run, Judge Sets Longest Game Streak for Strikeouts
Los Angeles Dodgers Move 50 Games Over .500
Los Angeles Dodgers Move 50 Games Over .500
Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Bryce Harper Latest Star to Suffer Injury
Bryce Harper Latest Star to Suffer Injury


Leave a Reply

 
© 2006-2017 BBNS.